A HUMANIZED CELIAC DISEASE MOUSE MODEL REFLECTS HISTOLOGIC AND IMMUNE EFFECTS OF TRANSGLUTAMINASE INHIBITION IN PATIENTS
Aline Pesi, Manuel A. Encalada-Ventura, Hicham El Mard, Victor F. Zevallos et autres
0 citationsGastroenterology
Rambabu Surabattula
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
48Publications signalées
1459Citations signalées
2Affiliations récentes
Institutions déclarées
Domaines associés
Liver Disease Diagnosis and TreatmentLiver physiology and pathologyLiver Diseases and ImmunityLiver Disease and TransplantationCeliac Disease Research and Management
Publications récentes
Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study
Michael Pavlides, Yasaman Vali, Ferenc E. Mózes, Kristy Wonders et autres
2 citationsNature Medicine
Su2156 SERUM THROMBOSPONDIN-2 IS A RELIABLE PREDICTOR OF IMPROVED LIVER FIBROSIS AND INFLAMMATION IN HBV PATIENTS UNDERGOING MULTIMODAL ANTIVIRAL THERAPY
Rambabu Surabattula, Shuyan Chen, Tongtong Meng, Sudharani Myneni et autres
0 citationsGastrointestinal Endoscopy
Su2061 THROMBOSPONDIN-2 PREDICT IMPROVED METABOLISM AND ATTENUATED LIVER FIBROGENESIS IN SEVERELY OBESE PATIENTS UNDERGOING AN INTENSIVE WEIGHT-LOSS THERAPY
Rambabu Surabattula, Nathalie Rohmann, Julia Koppenhagen, Alexia Beckmann et autres
0 citationsGastroenterology
Su2156 SERUM THROMBOSPONDIN-2 IS A RELIABLE PREDICTOR OF IMPROVED LIVER FIBROSIS AND INFLAMMATION IN HBV PATIENTS UNDERGOING MULTIMODAL ANTIVIRAL THERAPY
Rambabu Surabattula, Shuyan Chen, Tongtong Meng, Sudharani Myneni et autres
0 citationsGastroenterology
Su2061 THROMBOSPONDIN-2 PREDICT IMPROVED METABOLISM AND ATTENUATED LIVER FIBROGENESIS IN SEVERELY OBESE PATIENTS UNDERGOING AN INTENSIVE WEIGHT-LOSS THERAPY
Rambabu Surabattula, Nathalie Rohmann, Julia Koppenhagen, Alexia Beckmann et autres
0 citationsGastrointestinal Endoscopy
WED-213 Hepatic antifibrotic response by fibrogenesis markers in patients with MASLD undergoing a 6-month randomized dietary trial
Angelo Armandi, Lorenza Vaira, Rambabu Surabattula, Diana Julie Leeming et autres
0 citationsJournal of Hepatology
FRI-323 Matricellular serum biomarkers predict fibrosis severity and clinical outcomes in autoimmune hepatitis and primary biliary cholangitis
Ludwig Horst, Rambabu Surabattula, Alexander Fierenz, Füssel Katja et autres
0 citationsJournal of Hepatology
Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort
Vlad Ratziu, Rambabu Surabattula, Elisabetta Bugianesi, Jörn M. Schattenberg et autres
10 citationsGut
WED-382-YI Thrombospondin-2, a direct serum marker of fibrogenesis, to assess treatment response in MASLD in a 6-month lifestyle intervention program
Angelo Armandi, Rambabu Surabattula, Chiara Rosso, Gian Paolo Caviglia et autres
0 citationsJournal of Hepatology
FRI-425 Thrombospondin-2 reflects improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy
Rambabu Surabattula, Nathalie Rohmann, Julia Koppenhagen, Alexia Beckmann et autres
0 citationsJournal of Hepatology
TOP-394 Comprehensive analysis of biomarker performance targeting “advanced fibrosis” and “at-risk” metabolic-dysfunction associated steatotic liver disease (MASH) – primary analysis of the LITMUS study cohort
Yasaman Vali, Kristy Wonders, Guruprasad P. Aithal, R. Aller et autres
0 citationsJournal of Hepatology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.